Ken Griffin Bio N Tech Se Transaction History

Citadel Advisors LLC

$618 Billion
Q3 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bio N Tech Se stock. As of the latest transaction made, Citadel Advisors LLC holds 389,495 shares of BNTX stock, worth $40.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

389,495

Previous 135,600 187.24%

Holding current value

$40.2 Million

Previous $14.4 Million 166.06%

% of portfolio

0.01%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$96.22 - $115.31 $37.2 Million - $44.6 Million	386,783 Added 14261.91%	389,495 $38.4 Million
Q2 2025 Aug 14, 2025	SELL	$86.65 - $120.54 $18.9 Million - $26.3 Million	-218,478 Reduced 98.77%	2,712 $288,000
Q1 2025 May 15, 2025	BUY	$91.06 - $126.88 $8.54 Million - $11.9 Million	93,759 Added 73.58%	221,190 $20.1 Million
Q4 2024 Feb 14, 2025	BUY	$99.72 - $122.68 $8.83 Million - $10.9 Million	88,527 Added 227.55%	127,431 $14.5 Million
Q3 2024 Nov 14, 2024	SELL	$78.36 - $124.66 $2.14 Million - $3.4 Million	-27,308 Reduced 41.24%	38,904 $4.62 Million

Q2 2024 Aug 14, 2024	SELL	$80.36 - $102.87 $33.2 Million - $42.5 Million	-412,668 Reduced 86.17%	66,212 $5.32 Million
Q1 2024 May 15, 2024	BUY	$88.96 - $112.35 $39.9 Million - $50.4 Million	448,933 Added 1499.09%	478,880 $44.2 Million
Q4 2023 Feb 14, 2024	SELL	$90.91 - $112.75 $2.56 Million - $3.18 Million	-28,199 Reduced 48.5%	29,947 $3.16 Million
Q3 2023 Nov 14, 2023	SELL	$98.5 - $125.08 $13.4 Million - $17 Million	-136,062 Reduced 70.06%	58,146 $6.32 Million
Q2 2023 Aug 14, 2023	BUY	$102.58 - $129.66 $19.2 Million - $24.3 Million	187,519 Added 2803.39%	194,208 $21 Million
Q1 2023 May 15, 2023	SELL	$122.57 - $153.67 $15.4 Million - $19.3 Million	-125,602 Reduced 94.94%	6,689 $833,000
Q4 2022 Feb 14, 2023	BUY	$118.43 - $186.05 $12.9 Million - $20.2 Million	108,750 Added 461.96%	132,291 $19.9 Million
Q3 2022 Nov 14, 2022	SELL	$127.65 - $183.11 $33.7 Million - $48.4 Million	-264,344 Reduced 91.82%	23,541 $3.18 Million
Q2 2022 Aug 15, 2022	BUY	$123.25 - $186.24 $14.4 Million - $21.8 Million	116,888 Added 68.36%	287,885 $42.9 Million
Q1 2022 May 16, 2022	SELL	$126.25 - $231.85 $8.87 Million - $16.3 Million	-70,295 Reduced 29.13%	170,997 $29.2 Million
Q4 2021 Feb 14, 2022	SELL	$216.64 - $362.52 $7.76 Million - $13 Million	-35,808 Reduced 12.92%	241,292 $62.2 Million
Q3 2021 Nov 15, 2021	BUY	$205.93 - $447.23 $13.3 Million - $28.9 Million	64,532 Added 30.36%	277,100 $75.6 Million
Q2 2021 Aug 16, 2021	BUY	$113.32 - $241.49 $1.65 Million - $3.51 Million	14,535 Added 7.34%	212,568 $47.6 Million
Q1 2021 May 17, 2021	SELL	$85.73 - $119.5 $5.89 Million - $8.21 Million	-68,705 Reduced 25.76%	198,033 $21.6 Million
Q4 2020 Feb 16, 2021	BUY	$72.71 - $129.54 $9.03 Million - $16.1 Million	124,192 Added 87.12%	266,738 $21.7 Million
Q3 2020 Nov 16, 2020	SELL	$57.81 - $104.17 $12.3 Million - $22.1 Million	-212,615 Reduced 59.86%	142,546 $9.87 Million
Q2 2020 Aug 14, 2020	BUY	$38.58 - $66.74 $13.7 Million - $23.7 Million	355,161 New	355,161 $23.7 Million

Others Institutions Holding BNTX

# of Institutions

319

Shares Held

43.6M

Call Options Held

1.15M

Put Options Held

1.36M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $25B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account